(Q37729881)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20386760%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

review article

1 reference

title

C-reactive protein: risk factor, biomarker and/or therapeutic target? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20386760%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

0 references

0 references

Jacques Genest

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20386760%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

publication date

1 March 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20386760%20AND%20SRC:MED&resulttype=core&format=json

The Canadian Journal of Cardiology

30 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20386760%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

volume

26 Suppl A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20386760%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

page(s)

41A-44A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20386760%20AND%20SRC:MED&resulttype=core&format=json

C-reactive protein: a critical update

30 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

Novel and conventional biomarkers for prediction of incident cardiovascular events in the community

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

The metabolic syndrome--a new worldwide definition

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

Metabolic syndrome and risk of cardiovascular disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

C-reactive protein comes of age.

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

Genetically elevated C-reactive protein and ischemic vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

No effect of C-reactive protein on early atherosclerosis in LDLR-/- / human C-reactive protein transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

Continuously-infused human C-reactive protein is neither proatherosclerotic nor proinflammatory in apolipoprotein E-deficient mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

Targeting C-reactive protein for the treatment of cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

Inflammation and atherosclerosis: role of C-reactive protein in risk assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0828-282X%2810%2971061-8

7 January 2021

10.1016/S0828-282X(10)71061-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20386760%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference